KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Emergent BioSolutions (EBS) Revenue (2016 - 2025)

Historic Revenue for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to $231.1 million.

  • Emergent BioSolutions' Revenue fell 2134.1% to $231.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $788.9 million, marking a year-over-year decrease of 1432.45%. This contributed to the annual value of $1.0 billion for FY2024, which is 54.32% down from last year.
  • As of Q3 2025, Emergent BioSolutions' Revenue stood at $231.1 million, which was down 2134.1% from $140.9 million recorded in Q2 2025.
  • Emergent BioSolutions' Revenue's 5-year high stood at $732.9 million during Q4 2021, with a 5-year trough of $50.0 million in Q2 2024.
  • Over the past 5 years, Emergent BioSolutions' median Revenue value was $276.6 million (recorded in 2023), while the average stood at $282.8 million.
  • As far as peak fluctuations go, Emergent BioSolutions' Revenue crashed by 8520.27% in 2024, and later surged by 18180.0% in 2025.
  • Over the past 5 years, Emergent BioSolutions' Revenue (Quarter) stood at $732.9 million in 2021, then plummeted by 54.95% to $330.2 million in 2022, then fell by 16.23% to $276.6 million in 2023, then fell by 29.61% to $194.7 million in 2024, then grew by 18.7% to $231.1 million in 2025.
  • Its last three reported values are $231.1 million in Q3 2025, $140.9 million for Q2 2025, and $222.2 million during Q1 2025.